209 related articles for article (PubMed ID: 33301805)
1. Clinicopathologic characterization of enfortumab vedotin-associated cutaneous toxicity in patients with urothelial carcinoma.
Hirotsu KE; Rana J; Wang JY; Raghavan SS; Rieger KE; Srinivas S; Fan AC; Kwong BY; Novoa RA; Zaba LC
J Am Acad Dermatol; 2021 Dec; 85(6):1610-1611. PubMed ID: 33301805
[No Abstract] [Full Text] [Related]
2. Cutaneous toxicity associated with enfortumab vedotin treatment of metastatic urothelial carcinoma.
Wu S; Adamson AS
Dermatol Online J; 2019 Feb; 25(2):. PubMed ID: 30865407
[TBL] [Abstract][Full Text] [Related]
3. Enfortumab vedotin and pembrolizumab combination as a relevant game changer in urothelial carcinoma: What is left behind?
Bellmunt J; Nadal R
Med; 2024 Jun; 5(6):490-492. PubMed ID: 38878766
[TBL] [Abstract][Full Text] [Related]
4. Clinical and direct immunofluorescence characteristics of cutaneous toxicity associated with enfortumab vedotin.
Penny CL; Quow K; Rundle CW; Al-Rohil RN; Cardones AR; Kheterpal MK; Fresco AI
Br J Dermatol; 2022 Jul; 187(1):126-127. PubMed ID: 35048357
[TBL] [Abstract][Full Text] [Related]
5. New treatments for patients with progressive metastatic urothelial carcinoma.
Rosenberg JE
Clin Adv Hematol Oncol; 2021 Mar; 19(3):180-183. PubMed ID: 33739967
[No Abstract] [Full Text] [Related]
6. Clinical Overview of Enfortumab Vedotin in the Management of Locally Advanced or Metastatic Urothelial Carcinoma.
Hanna KS
Drugs; 2020 Jan; 80(1):1-7. PubMed ID: 31823332
[TBL] [Abstract][Full Text] [Related]
7. Use of enfortumab vedotin in an HIV-positive patient with urothelial carcinoma.
Azizi A; Houshyar R; Mar N
J Oncol Pharm Pract; 2022 Jul; 28(5):1226-1229. PubMed ID: 35043748
[TBL] [Abstract][Full Text] [Related]
8. Enfortumab vedotin-ejfv for the treatment of advanced urothelial carcinoma.
Mantia CM; Sonpavde G
Expert Rev Anticancer Ther; 2022 May; 22(5):449-455. PubMed ID: 35466857
[TBL] [Abstract][Full Text] [Related]
9. Atezolizumab-associated vitiligo-like leukoderma in a patient with transitional cell carcinoma.
Turner N; Leventhal J
Int J Dermatol; 2018 Oct; 57(10):e90-e92. PubMed ID: 30091457
[No Abstract] [Full Text] [Related]
10. Re: Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
Bedke J; Maas M
Eur Urol; 2021 Aug; 80(2):257-258. PubMed ID: 33895011
[No Abstract] [Full Text] [Related]
11. Cutaneous and Renal Toxicities of Enfortumab Vedotin for Advanced Urothelial Carcinoma: The UROKYU Study.
Furubayashi N; Minato A; Tomoda T; Masaoka H; Hori Y; Kiyoshima K; Negishi T; Haraguchi Y; Koga T; Song Y; Harada K; Kuroiwa K; Seki N; Fujimoto N; Nakamura M;
Anticancer Res; 2024 Jul; 44(7):3025-3032. PubMed ID: 38925809
[TBL] [Abstract][Full Text] [Related]
12. Enfortumab Vedotin in Advanced Urothelial Carcinoma.
Yeon SH; Lee HJ
N Engl J Med; 2021 Jul; 385(1):93. PubMed ID: 34192440
[No Abstract] [Full Text] [Related]
13. Enfortumab Vedotin in Advanced Urothelial Carcinoma. Reply.
Petrylak DP; Powles T; Rosenberg JE
N Engl J Med; 2021 Jul; 385(1):93-94. PubMed ID: 34192441
[No Abstract] [Full Text] [Related]
14. The biology and rationale of targeting nectin-4 in urothelial carcinoma.
Heath EI; Rosenberg JE
Nat Rev Urol; 2021 Feb; 18(2):93-103. PubMed ID: 33239713
[TBL] [Abstract][Full Text] [Related]
15. Harnessing potent therapies with care: enfortumab vedotin plus pembrolizumab for advanced-stage urothelial carcinoma.
Ghatalia P; Plimack ER
Nat Rev Clin Oncol; 2023 Dec; 20(12):818-819. PubMed ID: 37667009
[No Abstract] [Full Text] [Related]
16. Drug extravasation with Enfortumab vedotin.
Grant CR; de Kouchkovsky D; Kalebasty AR; Mar N
J Oncol Pharm Pract; 2023 Oct; 29(7):1789-1792. PubMed ID: 37401244
[TBL] [Abstract][Full Text] [Related]
17. Profile of Enfortumab Vedotin in the Treatment of Urothelial Carcinoma: The Evidence to Date.
Moussa M; Papatsoris A; Abou Chakra M; Dellis A
Drug Des Devel Ther; 2021; 15():453-462. PubMed ID: 33603337
[TBL] [Abstract][Full Text] [Related]
18. Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma.
Powles T; Rosenberg JE; Sonpavde GP; Loriot Y; Durán I; Lee JL; Matsubara N; Vulsteke C; Castellano D; Wu C; Campbell M; Matsangou M; Petrylak DP
N Engl J Med; 2021 Mar; 384(12):1125-1135. PubMed ID: 33577729
[TBL] [Abstract][Full Text] [Related]
19. Enfortumab vedotin to treat urothelial carcinoma.
Hanna KS
Drugs Today (Barc); 2020 May; 56(5):329-335. PubMed ID: 32406880
[TBL] [Abstract][Full Text] [Related]
20. Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era.
Kita Y; Ito K; Sano T; Hashimoto K; Mochizuki T; Shiraishi Y; Araki H; Fujiwara M; Kanamaru S; Takahashi T; Hishiki K; Okada T; Ogawa K; Ito M; Kojima T; Nishiyama N; Matsui Y; Nishiyama H; Kitamura H; Kobayashi T
Int J Urol; 2022 Jul; 29(7):647-655. PubMed ID: 35304776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
